Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 31 - Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
Patents for A61P 31 - Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics (179,784)
06/2012
06/27/2012CN101591393B Hydrophobia-tetanus double titer human immunoglobulin, method for preparing same and application thereof in pharmacy
06/27/2012CN101563353B Antibacterial compounds and processes for its production
06/27/2012CN101501002B Non-nucleoside reverse transcriptase inhibitors
06/27/2012CN101466406B Use of alpha-toxin for treating and preventing staphylococcus infections
06/27/2012CN101454319B Novel heterocyclic compound or salt thereof and intermediate thereof
06/27/2012CN101450966B Polypeptide of antimicrobial agent and use
06/27/2012CN101433641B Oral Chinese medicinal composition as well as preparing, taking and quality inspecting methods and use thereof
06/27/2012CN101392232B Application of dominant suppressing mutant F427D as anthrax bacillus toxin inhibitor and vaccine
06/27/2012CN101343320B Anti-vibrio parahaemolyticus chicken yolk antibody, preparation method and application thereof
06/27/2012CN101333247B Antimicrobial peptide separated from skin of Northeast China brown frog and applications in antibacterials
06/27/2012CN101133038B HIV inhibiting 2-(4-cyanophenyl)-6-hydroxylaminopyrimidines
06/27/2012CN101066340B Compound externally applied tetrodotoxin ointment and its prepn
06/26/2012USRE43497 Anti-MIF antibodies
06/26/2012US8209131 Inflammation, allergic diseases, metastatic cancers, pathogen infections; glycosaminoglycan related molecules
06/26/2012US8207361 Tigecycline crystalline forms and processes for preparation thereof
06/26/2012US8207294 Treatment of Aspergillus infections with alpha thymosin peptides
06/26/2012US8207187 Use of pyrroloquinoline compounds to kill clinically latent microorganisms
06/26/2012US8207178 Fused pyrimidines as reverse transcriptase inhibitors
06/26/2012US8207175 Inhibitor compounds
06/26/2012US8207173 Benzimidazoles and analogs thereof as antivirals
06/26/2012US8206947 Human transmembrane proteins
06/26/2012US8206716 Methods of treating with anti-C5/C5a specific antibodies
06/26/2012US8206714 Methods for treating rheumatoid arthritis using human antibodies that bind human TNFa
06/26/2012US8206708 Vascular endothelial growth factor 2
06/26/2012US8206699 Myelination of congenitally dysmyelinated forebrains using oligodendrocyte progenitor cells
06/26/2012CA2575232C 5-substituted-2-phenylamino-benzamide as mek inhibitor
06/26/2012CA2536185C Drug delivery system by administrating fine particles to sub-tenon
06/26/2012CA2443857C Bisphosphonate conjugates and methods of making and using the same
06/26/2012CA2406225C Recombinant intracellular pathogen vaccines and methods for use
06/26/2012CA2395678C Antimicrobial compositions and methods of use
06/26/2012CA2371689C Preparations for the application of anti-infective and/or anti-inflammatory agents to external or internal parts of the human or animal body in functional and cosmetic tissue remodelling and repair treatment
06/26/2012CA2319713C Use of n-substituted-1,5-dideoxy-1,5-imino-d-glucitol compounds for treating hepatitis virus infections
06/21/2012WO2012083170A1 Anti-viral compounds
06/21/2012WO2012083138A2 Azole pharmaceutical formulations for parenteral administration and methods for preparing and using the same as treatment of diseases sensitive to azole compounds
06/21/2012WO2012083061A2 Anti-viral compounds
06/21/2012WO2012083059A1 Anti-viral compounds
06/21/2012WO2012083058A2 Anti-viral compounds
06/21/2012WO2012083053A2 Anti-viral compounds
06/21/2012WO2012083048A2 Anti-viral compounds
06/21/2012WO2012083043A1 Anti-viral compounds
06/21/2012WO2012082566A1 Sulfur derivatives as chemokine receptor modulators
06/21/2012WO2012082073A1 Human monoclonal antibody with specificity for dengue virus serotype 1 e protein and uses thereof
06/21/2012WO2012081713A1 Therapeutic agent for blood-brain barrier disruption syndrome
06/21/2012WO2012081673A1 Ophthalmic composition for contact lens
06/21/2012WO2012080953A1 Compounds useful for treating aids
06/21/2012WO2012080918A2 Wear resistant antimicrobial compositions and methods of use
06/21/2012WO2012080728A1 Imidazo [4, 5 -c] quinolin- 1 -yl derivative useful in therapy
06/21/2012WO2012080641A1 S1p receptor agonists and use thereof in treating hiv infections
06/21/2012WO2012080622A1 Algal extract-based composition for oro-dental use
06/21/2012WO2012080451A1 Imidazopyridines as respiratory syncytial virus antiviral agents
06/21/2012WO2012080450A1 Azaindoles as respiratory syncytial virus antiviral agents
06/21/2012WO2012080449A1 Azabenzimidazoles as respiratory syncytial virus antiviral agents
06/21/2012WO2012080447A1 Indoles as respiratory syncytial virus antiviral agents
06/21/2012WO2012080186A1 Composition and use of a fermented olive leaf product for the treatment of nail and skin infections.
06/21/2012WO2012080153A1 Use of substituted dimethoxyhydroxyphenylalkyl derivatives as preservative, preserving method, compounds and composition
06/21/2012WO2012079289A1 Amorphous powder and polymorph of carbapenem derivative, preparation method therefor and use thereof
06/21/2012WO2012079164A1 Activators of cylindrical proteases
06/21/2012WO2012079115A1 Immunostimulatory oligonucleotides
06/21/2012WO2012040170A3 Compositions and methods for treating tuberculosis
06/21/2012WO2012040164A3 Tlr5 ligands, therapeutic methods, and compositions related thereto
06/21/2012WO2012037078A3 Immunogenic respiratory syncytial virus glycoprotein-containing vlps and related compositions, constructs, and therapeutic methods
06/21/2012WO2012031090A9 Small molecule inhibitors of ebola and lassa fever viruses and methods of use
06/21/2012WO2012031045A3 Phosphonate ester derivatives and methods of synthesis thereof
06/21/2012WO2012027712A3 Potent and selective inhibitors of hepatitis c virus
06/21/2012WO2012012498A3 Use of trp channel agonists to treat infections
06/21/2012WO2010075517A3 Nucleoside phosphoramidate prodrugs
06/21/2012US20120159658 Extracellular vesicles derived from gram-positive bacteria, and use thereof
06/21/2012US20120157541 Soluble pharmaceutical formulations of n,n-diaminodiphenyl sulfone for optimal use in the treatment of various diseases
06/21/2012US20120157539 Nuclear receptor binding agents
06/21/2012US20120157538 Compounds for the Inhibition of Herpes Viruses
06/21/2012US20120157537 NMDA receptor antagonists and their use in inhibiting abnormal hyperphosphorylation of microtubule associated protein tau
06/21/2012US20120157529 Composition and Method for Prevention, Mitigation or Treatment of an Enteropathogenic Bacterial Infection
06/21/2012US20120157522 B. Anthracis Prevention and Treatment: Mutant B. Anthracis Lacking Luxs Activity and Furanone Inhibition of Growth, AI-2 Quorum Sensing, and Toxin Production
06/21/2012US20120157519 Tellerium-containing compounds for treating viral infections
06/21/2012US20120157512 Preventing and Curing Beneficial Insect Diseases Via Plant Transcribed Molecules
06/21/2012US20120157507 USP47 Inhibtors and Methods to Induce Apoptosis
06/21/2012US20120157494 Isoindolyl compounds
06/21/2012US20120157493 Antifungal and Antiparasitic Indoloquinoline Derivatives
06/21/2012US20120157492 Antibiotic drug
06/21/2012US20120157479 3-hydroxypyrrolidine inhibitors of 5'-methylthioadenosine phosphorylase and nucleosidase
06/21/2012US20120157462 Hydroxamic acid derivatives of aniline useful as therapeutic agents for treating anthrax poisoning
06/21/2012US20120157447 Quinolone Carboxylic Acids, Derivatives Thereof, and Methods of Making and Using Same
06/21/2012US20120157435 Antiviral Compounds
06/21/2012US20120157434 Antimicrobial heterocyclic compounds for treatment of bacterial infections
06/21/2012US20120157433 Heteroaryl Compounds as Kinase Inhibitors
06/21/2012US20120157428 Bromodomain inhibitors and uses thereof
06/21/2012US20120157412 Substituted Pyrimidinyl Oxime Kinase Inhibitors
06/21/2012US20120157404 Antiviral compounds
06/21/2012US20120157384 Mutants pf4 polypeptides exhibiting an increased anti-angiogenic activity
06/21/2012US20120157376 Pharmacologically active antiviral peptides and methods of their use
06/21/2012US20120157375 Identification of Inhibitors of a Bacterial Stress Response
06/21/2012US20120157374 Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same
06/21/2012US20120157373 Antimicrobial compounds having protective or therapeutic leaving groups
06/21/2012US20120157372 Human milk peptides
06/21/2012US20120157371 High penetration prodrug compositions of antimicrobials and antimicrobial-related compounds
06/21/2012US20120156649 Methods for treating dental diseases, disorders, and injuries
06/21/2012US20120156307 Medical uses of nanoclustered water
06/21/2012US20120156295 Antibiotic compounds
06/21/2012US20120156289 Biodegradable Osmotic Pump Implant For Drug Delivery
06/21/2012US20120156287 Use of Vitelline Protein B as a Microencapsulating Additive
1 ... 277 278 279 280 281 282 283 284 285 286 287 288 289 290 291 292 293 294 295 296 297 ... 1798